Fluorescence in situ hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 cases. by Vergier, B. et al.
Fluorescence in situ hybridization,
a diagnostic aid in ambiguous melanocytic
tumors: European study of 113 cases
Beatrice Vergier1, Martina Prochazkova-Carlotti1, Arnaud de la Fouchardie`re2,
Lorenzo Cerroni3, Daniela Massi4, Vincenzo De Giorgi4, Christiane Bailly2,
Ulrich Wesselmann5, Apollon Karlseladze6, Marie-Francoise Avril7, Thomas Jouary8
and Jean-Philippe Merlio1
1De´partement de Pathologie et Biologie des Tumeurs, EA2406, CHU Bordeaux-Universite´ Victor Segalen
Bordeaux 2, Hoˆpital Haut-Le´veˆque, CHU Pessac-Bordeaux, France; 2De´partement de Pathologie, Centre Le´on
Be´rard (CLCC), Lyon, France; 3Department of Dermatology, Medical University of Graz, Graz, Austria;
4Department of Pathology and Oncology, University of Florence, Florence, Italy; 5Department of Dermatology,
Helios Hospital Wuppertal, University of Witten-Herdecke, Witten-Herdecke, Germany; 6Department of
Pathology, Russian Cancer Research Centre, Moscow, Russia; 7Service de Dermatologie, Hoˆpital Tarnier,
Paris, France and 8Service de Dermatologie, Unite´ de Cance´rologie Cutane´e, Hoˆpital Saint Andre´,
Bordeaux, France
Some melanocytic tumors are ambiguous, so the reproducible histopathological diagnosis of benign or
malignant lesion is difficult. This study evaluated the contribution of fluorescence in situ hybridization (FISH)
first in 43 non-equivocal melanomas and nevi, and then in 113 ambiguous melanocytic tumors selected by
expert pathologists from six different European institutions. We included two groups of ambiguous tumors:
patients without recurrence (5-year minimal follow-up) and with metastases. An independent triple-blind
histopathological review was performed to classify tumors as ‘favor benign’ (A) or ‘favor malignant’ (Aþ ).
A four-color probe set targeting 6p25, 6q23, 11q13 and CEP6 was used for FISH. In the 43 non-equivocal
melanomas and nevi, sensitivity was 85% and specificity 90%. Ninety out of 95 ambiguous melanocytic tumors
included were FISH interpretable (67 FISH negative and 23 FISH positive). Of the 90 patients, 69 presented no
recurrence and 21/90 exhibited metastases. These ambiguous tumors were mostly spitzoid tumors (45/90).
Histopathological reviewers classified these tumors as favor malignant (49/90) and favor benign (32/90),
whereas nine cases had a discordant diagnosis. By comparison with outcome, the sensitivity and specificity of
histopathological review were 95 and 52%, and the sensitivity and specificity of FISH were 43 and 80%.
Compared with histopathological review, the sensitivity and specificity of FISH were 34.5 and 91%. Interestingly,
by combining the histopathological diagnosis with FISH results, the diagnosis was optimized, especially by
increasing specificity (76% instead of 52% for expert diagnosis alone) and by improving sensitivity compared
with FISH alone (90 vs 43% for FISH result alone). The value of this FISH test is to add a reproducible
demonstration of malignancy to the histopathological diagnosis, especially in doubtful/ambiguous melanocytic
tumors. A positive FISH test reinforces the diagnosis of melanoma, allowing such tumors (particularly thick
tumors) to be managed as melanomas.
Modern Pathology (2011) 24, 613–623; doi:10.1038/modpathol.2010.228; published online 10 December 2010
Keywords: ambiguous melanocytic tumors; FISH; melanoma; MELTUMP; nevus; Spitz
Some melanocytic lesions are difficult to diagnose
as truly benign or malignant and there is a subset of
ambiguous cases in which a specific and reprodu-
cible diagnosis is difficult or even impossible to
render. For problematic melanocytic lesions, a
second opinion from an expert dermatopathologist
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improves patient care in 27% of cases.1 However, a
complete agreement for difficult melanocytic
neoplasms was observed only in 54.5% and a high
level of disagreement (ie, benign vs malignant)
was found in 25% of cases among consultant
pathologists.1–5 Such ambiguous melanocytic tu-
mors are divided into thin and thick tumors.4
Thin ambiguous melanocytic lesions are frequently
encountered as dysplastic nevus or atypical
intraepidermal melanocytic proliferation, thus rais-
ing the diagnostic issue of atypical nevus or truly
superficial spreading thin or in situ melanoma.
Owing to the lack of reproducible diagnosis,
different names have been proposed, such as
‘melanocytic intraepidermal neoplasia (MIN)’6,7 or
‘superficial atypical melanocytic proliferations of
uncertain significance (SAMPUS)’.8 The prognosis
of such thin atypical melanocytic tumors is excel-
lent if they are completely excised, but a precise
diagnosis remains difficult to make. This is not the
case for ‘thick’ atypical melanocytic lesions, because
the consequences for therapy and prognosis are
more important. These thick ambiguous melanocy-
tic lesions called ‘melanocytic tumors of uncertain
malignant potential (MELTUMP)’ by Elder and Xu8
comprise melanocytic proliferations that form tu-
mors in the dermis, and are therefore potentially
capable of metastasis. The most frequent histologi-
cal subtypes included in this category are Spitz
tumors and melanoma simulating other types of
nevus, deep penetrating nevus or cellular blue
nevus.9 For both thick and thin ambiguous melano-
cytic lesions, new diagnostic and prognostic tools
are necessary for second opinion and may improve
diagnostic accuracy and reproducibility between
expert dermatopathologists.
Very recently, Gerami et al10 used a multicolor
fluorescence in situ hybridization (FISH)-based
test as a new tool to provide the highest
diagnostic discrimination between melanoma
and nevus. It allows detection of copy number
changes of chromosomal regions by the use of
locus-specific probes developed on the basis of
the presence of non-overlapping patterns of
chromosomal imbalances in melanoma and nevi.11
This technique is especially applicable to melano-
cytic lesions as it can be performed on sections
consecutive to those used for histopathological
analysis.
The aims of our study were first to perform FISH
analysis in 43 cases of non-equivocal melanomas
(23) and nevi (20) in a training set. Then, we
analyzed 113 cases of ambiguous melanocytic
tumors provided by six European centers to deter-
mine the relevance of such testing by comparison
with an expert panel review as well as with patients’
clinical course. For this purpose, we selected
ambiguous lesions in patients with at least 5 years
recurrence-free follow-up and in patients with
secondary regional metastasis (stage III) or distant
metastasis (stage IV) or death.
Materials and methods
As a training set, we first included 43 patients with
either non-equivocal melanomas (23 cases) or
typical nevi (20 cases) to evaluate applicability or
efficiency, sensitivity and specificity of the melano-
ma FISH test. All cases were provided by a
single dermatopathological department (Bordeaux).
Different histological subtypes of melanoma were
included: superficial spreading melanomas (11
cases), lentigo malignant melanoma (three cases),
acral lentiginous melanoma (three cases), unclassifi-
able melanomas (four cases) and desmoplastic
melanoma (two cases). The different subtypes of
nevi were common nevi (11 cases with one
junctional nevus, five dermal nevi and five com-
pound nevi), congenital nevi (four cases), common
blue nevi (two cases), Spitz or Reed nevi (three
cases) and genital type nevus (one case).
Secondly, we included 113 patients with ambig-
uous melanocytic tumors selected by expert pathol-
ogists in the field of melanoma working in six
different European institutions: L Cerroni (Graz,
Austria, 25 cases), D Massi (Firenze, Italy, 24 cases),
U Wesselmann (Wuppertal, Germany, seven cases),
A Karseladze (Moscow, Russia, seven cases), A de la
Fouchardiere (Lyon, France, 14 cases) and B Vergier
(Bordeaux, France, 36 cases). For this second step,
two groups of patients with ambiguous/atypical
melanocytic tumors were selected:
 patients without recurrence with a 5-year minimal
follow-up;
 patients with recurrences: to the regional lymph
nodes (stage III) or distant sites (stage IV) or death
from melanoma. We included only cases with
regional metastasis (stage III) or any type of distant
metastasis (stage IV). Cases with microscopic
metastatic lymph node deposits (micrometastasis)
were excluded, as their clinical relevance is not
fully resolved. For patients with in-transit cuta-
neous metastasis (stage III), we checked that the
initial re-excision was complete and that the
cutaneous metastasis was distant from the initial
scar to avoid inclusion of a local cutaneous
recurrence.
Homogeneity in data recording between centers
was reached using a detailed form for each patient.
Histopathological Review
An independent triple-blind histopathological re-
view of all cases was performed on one hematox-
ylin–eosin–saffron (HES)-stained slide of each case
by three expert French pathologists (CB, AF and BV)
without the knowledge of initial diagnosis, follow-
up or FISH results. The three pathologists had to
specify the degree of ambiguousness (0¼non-am-
biguous; 1¼ ambiguous and 2¼ very ambiguous).
Each pathologist had finally to classify the lesion
either as ambiguous melanocytic lesion ‘favor
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benign’ (A) or as ‘favor malignant’ (Aþ ). Finally, a
case was considered as ‘favor benign’ (A) if the
three pathologists agreed (AAA) and ‘favor
malignant’ (Aþ ) if at least two pathologists diag-
nosed the tumor as Aþ (because we favored the
diagnosis of malignancy and not of discordance
with two Aþ ). If only one out of three pathologists
disagreed (AþAA), the case was considered as
discordant (D).
FISH Analysis
Areas of interest for FISH analysis were selected on
HES-stained slides by a single pathologist (BV).
A four-color Vysis Melanoma FISH Probe kit from
Abbott Molecular Inc. (Abbott France, Rungis,
France) was used. This set of probes targets 6p25
(RREB1: Ras-responsive element-binding protein-1),
6q23 (MYB: myeloblastosis), 11q13 (CCDN1: cyclin
D1) and chromosome 6 centromere (CEP6). They are
labeled, respectively, with Spectrum Red, Spectrum
Gold, Spectrum Green and Spectrum Aqua. FISH
was performed on 5-mm sections of formalin-fixed
paraffin-embedded tissues according to the protocol
provided by Abbott Molecular Inc. Briefly, sections
were mounted on SuperFrost Plus positively
charged slides, baked at 561C overnight, deparaffi-
nized, submersed in 1SSC, pH 6.3, at 801C for
35min and washed in distilled water for 3min.
After protease digestion (4mg pepsin per ml in 0.2N
HCl) at 371C for 15min, sections were rinsed in
distilled water for 3min, passed through graded
ethanol and air-dried. Sections were co-denaturated
with probe at 731C for 5min and hybridized at 371C
overnight using an automated ThermoBrite co-
denaturation oven (Molecular Abbott Inc.). Next,
slides were placed in washing buffer (2SSC/0.3%
NP40; Abbott Molecular Inc.) at room temperature
for 2–10min to remove the coverslips and then
immersed in 731C washing buffer for 2min, air-dried
and mounted with Vectashield mounting medium
with DAPI (Vector laboratories, Burlingame, CA,
USA). The slides were analyzed with an epifluores-
cence microscope equipped with appropriate single
band-pass filters (Abbott Molecular Inc.). Tumor-
bearing areas were selected using DAPI filter at low
magnification ( 20 objective), and then evaluated
for the presence of nuclei-harboring abnormal copy
numbers of any probe. FISH analysis was performed
by a trained cytogenetics specialist (MC) indepen-
dently of the diagnosis and follow-up of patients.
The slide was considered as interpretable if the
following requirements were fulfilled: (1) signals
bright, distinct and easily evaluable; (2) background
relatively free of fluorescent particles or haziness;
and (3) nuclei not overlapping to avoid false
counting. For unsatisfactory cases, the FISH proce-
dure on fresh slides was repeated three times with
some modifications before considering the case as
uninterpretable.
The entire section was examined to visually select
clusters with an abnormal profile, and areas of
interest selected by the pathologist were especially
inspected. Three abnormal areas with the most
significant copy number changes were selected for
counting. Thirty nuclei were analyzed under high
power ( 100) objective. The criteria for FISH
positivity were provided recently by Gerami
et al:10 (A) gain in RREB1 relative to CEP6 greater
than 55%; (B) gain in RREB1 greater than 29%; (C)
loss of MYB relative to CEP6 greater than 40% and
(D) gain in CCDN1 greater than 38%. The cases were
considered as polyploid when all signals were
simultaneously greater than 2 in the majority of
nuclei examined.
Statistical Analysis
For non-equivocal melanocytic tumors, the sensi-
tivity of the FISH assay was determined using
histopathological diagnosis as a gold standard. For
ambiguous melanocytic tumors, sensitivity of the
assay was determined first using patients’ outcome
and then histopathological diagnosis of the three
pathologists as a gold standard. Sensitivity of
histopathological review was determined using
outcome. SAS version 8.2, on a UNIX operating
system, was used to analyze the data. Kaplan–Meier
curves were constructed using Proc LIFETEST in
SAS. A multivariate survival analysis with a Cox
regression model was used to determine the impact
of age (under 17 years, range 17–59 years, 459
years), location (axial vs extremities), FISH result
and histopathological expert diagnosis, respectively.
The hazard ratio of the FISH status effect on
metastasis from the unadjusted Cox regression
model was estimated using Proc PHREG.
Results
FISH Results in Non-equivocal Melanomas and Nevi
Among the 43 cases, only four were found unin-
terpretable by FISH according to our guidelines
(efficiency 91%), probably due to the fixation
procedure. Seventeen out of 19 nevi (89.5%) were
negative (Table 1). The two FISH-positive nevi cases
were positive for only one criterion: RREB1 gain for
one (consequence of chromosome 6 trisomy) and
MYB deletion for the other (Figure 1). Seventeen out
of 20 melanomas (85%) were FISH positive. Simi-
larly, four out of 17 melanomas were positive for
only one criterion, whereas nine (53%) and four
(23.5%) malignant cases were positive for two and
three criteria, respectively. The most frequent
criteria found positive were RREB1 gain (12/17,
71%), followed by MYB deletion (11/17, 65%). Both
acral lentiginous melanoma cases presented the
same profile with CCDN1 gain and MYB deletion.
For the other melanoma subtypes, there were several
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positive criteria. Among melanomas, the three FISH-
negative cases were superficial spreading melanoma
thinner than 2mm (Table 1). Altogether, in these
non-equivocal melanocytic lesions, we achieved
sensitivity 85%, specificity 90%, positive predictive
value 89.5% and negative predictive value 86%.
FISH Results in the Ambiguous Melanocytic Tumors
Eighteen out of 113 cases initially selected were
excluded owing to incomplete follow-up data or less
than 5 years recurrence-free follow-up (eight cases),
micrometastasis (three cases), doubt between cuta-
neous recurrence and in-transit cutaneous metasta-
sis (three cases), inappropriate fixative such as
Bouin’s fluid (three cases) and insufficient number
of melanocytic cells on new sections (one case).
Ninety out of 95 were interpretable (efficiency 95%).
Out of 90 ambiguous melanocytic lesions, 67 cases
(74.5%) were determined as FISH negative and 23
cases (25.5%) as FISH-positive (Table 2). Among the
23 FISH-positive cases, there were five cases with
three positive criteria, 11 cases with two criteria and
seven cases with one criterion.
Clinical and follow-up data
Fifty-two women and 38 men were included (sex
ratio: 1.4), with a mean age of 33 years (range: 4–73
years). Nine cases concerned pre-pubescent chil-
dren (under 11 years). Sixty-nine out of 90 patients
(77%) had a recurrence-free follow-up of at least 5
years, with a mean follow-up of 9 years (range: 5–19
years). Twenty-one patients (23%) exhibited
Table 1 Data of the 39 non-equivocal melanomas and nevi
Case Age Sex Site Subtype Breslow’s
depth (mm)
FISH
result
Melanomas
1 69 F Scalp SSM 1.2 
2 48 F Trunk SSM 1.2 
3 85 M Thigh SSM 2 
4 65 M Shoulder SSM 1.85 +B,D
5 48 M Trunk SSM 15 +B,D
6 77 M ? SSM 2.15 +A,B
7 96 M Shoulder SSM 1 +B,C
8 82 M Trunk SSM 1.8 +C
9 72 M Face SSM 3.6 +C
10 70 M Arm SSM 1.32 +B,D
11 74 M Neck LMM 4 +B,C
12 69 F Face LMM 0.2 +B,D
13 85 M Face LMM 4.7 +A,B,C
14 86 F Acral ALM 0.58 +C,D
15 62 M Acral ALM 1.8 +C,D
16 89 F Arm Unclassifiable 7.41 +A,B,C
17 40 F Leg Unclassifiable 26 +A,B,C
18 74 M Scalp Unclassifiable 7 +C
19 73 M Arm Unclassifiable 5.7 +B,C,D
20 60 F Scalp Desmoplastic 7 +B
Nevi
1 50 M Trunk Junctional 
2 5 F Scalp Compound +C
3 15 F Finger Compound 
4 34 M Trunk Compound 
5 72 M Trunk Compound +B
6 49 F Chin Dermal 
7 65 M Foot Dermal 
8 66 M Face Dermal 
9 29 M Neck Dermal 
10 7 M Buttock Congenital 
11 4 M Knee Congenital 
12 47 M Trunk Congenital 
13 22 M Trunk Congenital 
14 28 M Trunk Blue nevus 
15 36 F Leg Blue nevus 
16 3 F Leg Spitz–Reed 
17 13 M Thigh Spitz–Reed 
18 43 M Thigh Spitz–Reed 
19 18 F Vulvar Genital type 
Abbreviations: ALM: acral lentiginous melanoma; LMM: lentiginous malignant melanoma; SSM: superficial spreading melanoma.
FISH result: negative (); positive (+): A¼RREB1/CEP6 gain; B¼RREB1 gain; C¼MYB/CEP6 loss; and D¼CCDN1 gain.
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regional (stage III¼ 12 cases) or distant metastases
(stage IV¼ 9 cases; lung, liver, bone, spleen, regional
parotid or brain metastases). Among patients with
stage III, 10 had lymph node metastases and two
in-transit cutaneous metastases. Mean follow-up of
patients with a poor course was 4 years (range: 6
months–20 years).
Histopathological review
The ambiguity of the lesion as determined by the
first dermatopathologist was confirmed by the panel
of three reviewers in all cases. These ambiguous
lesions were classified mostly as spitzoid tumors
(45/90 cases, 50%), deep penetrating tumors (atypi-
cal or raising the question of melanoma simulating a
deep penetrating naevus, 10 cases), nevoid melano-
ma (eight cases), cellular blue nevus or melanoma-
simulating cellular blue nevus (seven cases), super-
ficial spreading melanoma with radial growth phase
(five cases) or vertical growth phase (three cases),
atypical acral tumor (three cases) and other types of
atypical nevus (nine cases). The majority of ambig-
uous melanocytic tumors (49/90, 54%) were diag-
nosed as ‘favor malignant’ (Aþ ) by the three
pathologists (41/49 cases) or by two of the three
pathologists (8/49 cases). Thirty-two (32/90, 36%)
were diagnosed as ‘favor benign’ (A) and nine
(10%) had a discordant diagnosis (D). These nine
discordant cases were recurrence free over a 5-year
follow-up. Twenty out of 49 patients (41%) diag-
nosed as ‘favor malignant’ presented metastases.
Among the 32 tumors classified as ‘favor benign’, all
had a 5-year recurrence-free follow-up, except one
patient with a histological diagnosis of cellular blue
nevus presenting with lung metastases. By compar-
ison with outcome, the sensitivity and specificity of
histopathological review were, respectively, 95 and
52%. Positive and negative predictive values were
41 and 97%.
Comparison of FISH results with outcome
Fifty-five out of 69 cases (80%) with 5-year
recurrence-free follow-up were FISH negative for
all criteria and 14 (20%) were FISH positive for at
least one criterion (five cases for one criterion, seven
cases for two criteria and two cases for three
criteria). Among 21 patients with a secondary
tumoral event, nine (43%) were FISH positive (two
cases for one criterion, four cases for two criteria and
three cases for three criteria). The number of
abnormalities was not proportional to the course of
the disease. By comparison with outcome, the
sensitivity and specificity of this FISH analysis
were, respectively, 43 and 80%; positive predictive
Figure 1 Example of fluorescence in situ hybridization (FISH)-positive nevus. (a) Compound nevus without atypia (hematoxylin–eosin–
saffron (HES)100). (b) FISH-positive result in the dermal component: cyclin D1 (CCDN1)/Ras-responsive element-binding protein-1
(RREB1)/myeloblastosis (MYB)/chromosome 6 centromere (CEP6) signals: 2/2/1/2 (*nuclei showing MYB deletion). (c) FISH-negative
result in the normal epidermis (internal negative control): CCDN1/RREB1/MYB/CEP6 signals: 2/2/2/2 (*nuclei showing normal profile).
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Table 2 Characteristics of ambiguous melanocytic tumors
Type of ambiguous
tumor
Case no. Age a Sex Expert
diagnosis b
FISH c Adverse event
Spitz tumor 2 31 F A+  —
5 20 F A+  —
12 28 F A+  —
78 42 M A+  —
82 36 M A+  —
89 34 F A+  —
92 8 F A+  —
93 32 M A+  —
99 26 F A+  —
101 42 F A+  —
102 20 F A+  —
15 18 F A+  Cutaneous/lung/liver M
52 14 M A+  Subcutaneous M (+LN micro-M)
53 16 M A+  Subcutaneous/peritoneal/brain M
64 6 F A+  Lymph node M
67 56 F A+  Lymph node/parotid/pancreas/liver/bone/spleen
M (dead from melanoma)
6 70 M A+ +A,B,C —
59 51 F A+ +C —
88 20 M A+ +B,D —
91 6 F A+ +B,D —
95 20 F A+ +B,D —
97 33 M A+ +B,D —
10 20 F A+ +D Lymph node M
13 28 F A+ +A,B Lymph node M
37 56 M A+ +B,D Lymph node M (dead from melanoma)
51 23 F A+ +B,D Lymph node M
56 12 M A+ +B,C,D Subcutaneous M
107 42 F A+ +C Lymph node/lung/liver M
11 21 M A  —
21 53 M A  —
34 14 M A  —
38 4 M A  —
48 20 F A  —
49 46 F A  —
76 44 F A  —
96 6 M A  —
103 44 F A  —
105 11 F A  —
108 33 M A  —
110 17 F A  —
114 24 F A  —
87 13 F A +D —
104 23 M D  —
40 37 F D +A,B —
47 23 M D +C —
DPN 57 43 M A+  Lymph node M
58 28 F A+  Lymph node/liver M
83 43 M A+  Lymph node M
1 10 F A  —
69 30 M A  —
86 20 F A  —
106 7 M A  —
72 64 F D  —
19 12 M D  —
71 44 F D  —
CBN 68 67 M A+ +A,B,C Lymph node M (dead)
25 71 F A  —
27 19 F A  —
54 53 M A  Lymph node /lung M
45 26 M A +B —
70 5 M A  —
26 55 M D  —
Nevoid melanoma 17 73 F A+  —
16 41 F A+  Lymph node M
20 37 F A+  —
63 67 M A+ +A,B —
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value and negative predictive value were 39 and
82%, respectively. Survival analysis (Kaplan–Meier
method) showed a trend for a worse prognosis for
FISH-positive patients (Figure 2), although this did
not reach the statistical threshold (P¼ 0.07) in this
small series. The sensitivity of FISH in the Spitz
tumor group was higher than that in the overall
cases (54.5%).
Comparison of FISH results with histopathological
diagnosis
In the ‘favor benign’ category (A), 90% of cases
(29/32) were FISH negative and only three cases
were FISH positive with only one positive criterion
(see Table 2). In the ‘favor malignant’ category of
ambiguous cases, 37% of cases (18/49) were FISH
positive for at least one criterion (three cases for one
criterion, 10 cases for two criteria and five cases for
three criteria) (eg, see Figure 3). On the other hand,
among 23 FISH-positive cases, 18 (78%) were finally
diagnosed as Aþ , 3/23 (13%) as A and 2/23 (9%)
as D. The main positive criteria were RREB1 gain
(17/23, 74%), followed by CCDN1 gain (11/23, 48%)
and MYB deletion (10/23, 43%). Among 23 FISH-
positive cases, nine cases (39%) were polyploid.
Interestingly, eight of these nine cases corresponded
to Spitz tumors with seven ‘favor malignant’ and
one ‘favor benign’. One ‘favor malignant’ polyploid
case was a nevoid melanoma (case 84). The only
‘favor benign’ FISH-positive Spitz tumor was not
polyploid (case 87). Among discordant (D) cases,
seven out of nine were FISH-negative cases and two
were FISH-positive cases (see Table 2) and classified
as Spitz tumors. Excluding discordant cases, sensi-
tivity and specificity of FISH compared with
histopathological diagnosis were, respectively, 36.7
and 90.6% (positive predictive value 86% and
Table 2 Continued
Type of ambiguous
tumor
Case no. Age a Sex Expert
diagnosis b
FISH c Adverse event
66 56 M A+ +B,C,D Bone M
84 41 F A+ +B,D —
85 12 M A+  —
109 50 M A+ +A,B,C —
SSM
RGP 18 28 F A+  —
RGP 24 23 F A+  —
RGP 30 54 F A+  —
RGP 98 40 F A+  —
RGP 113 30 F A+  —
VGP 65 54 M A+  —
VGP 32 45 F A+  Lymph node M (dead)
VGP 4 44 F A+  Cutaneous/lymph node/lung/liver M
Others
ALM 31 54 F A+ +B,C Lung M (dead)
Acral Nevus 41 6 M A  —
Acral Nevus 23 28 F A  —
Compound N 79 36 F A +C —
Compound N 44 46 F A  —
Junctional N 112 25 F A  —
Combined N 28 18 M A  —
Combined N 42 28 F A  —
Congenital N 29 51 M A  —
Congenital N 94 53 M A  —
Atypical N 81 38 F D  —
Atypical N 61 35 M D  —
Abbreviations: M: metastasis; DPN: deep penetrating nevus type; CBN: cellular blue nevus type tumor; SSM: superficial spreading melanoma;
RGP: radial growth phase; VGP: vertical growth phase; ALM: acral lentiginous melanoma.
a
Age at diagnosis.
b
Expert final histopathological diagnosis: favor malignant (A+); favor benign (A) and discordant (D).
c
FISH result: positive (+), negative (): A¼RREB1/CEP6 gain; B¼RREB1 gain; C¼MYB/CEP6 loss; and D¼CCDN1 gain.
Figure 2 Kaplan–Meier curve—survival analysis (fluorescence
in situ hybridization (FISH) result vs outcome).
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negative predictive value 48%). Even if discordant
cases were included as ‘favor malignant’ (as one
pathologist thought it was malignant), sensitivity
and specificity were, respectively, 34.5 and 91%,
with positive predictive value 87% and negative
predictive value 43%.
Combination of FISH results and histopathological
diagnosis vs outcome
Interestingly, by combining the histopathological
diagnosis with FISH results and by considering
cases as truly malignant only if histopathological
diagnosis was ‘favor malignant’ (Aþ ) and FISH
positive, the diagnosis was optimized, especially by
increasing specificity (76% instead of 52% for
expert diagnosis alone), and also by improving
sensitivity compared with FISH alone (90 vs 43%
for FISH result alone). Multivariate Cox regression
showed that only expert diagnoses were statistically
significant compared with metastases P¼ 0.0064
(Table 3).
Discussion
This new FISH assay was first evaluated by Gerami
et al10 on a cohort of 83 melanomas and 86 typical
nevi, with a sensitivity of 86.7% and a specificity of
95.4%. Their results were confirmed by the study of
Morey et al12 on 10 metastases of melanomas, 10
primary melanomas and 10 nevi showing a sensi-
tivity of 90% and a specificity of 95%, and more
recently by a new study by Gerami et al13 on 110
nevi and 123 melanoma (sensitivity 83% and
specificity 94%). Using the same updated threshold
value on a series of 20 non-ambiguous melanomas
and 19 nevi, we observed quite similar sensitivity of
85% and specificity of 90%. In our study, two out of
19 nevi were FISH positive as well as 4/86 nevi in
the study by Gerami and 1/10 nevi in Morey’s study.
Our two cases as well as Morey’s nevus had only one
positive criterion. No criterion other than histo-
pathological review can be used to consider such
cases as truly benign and therefore as ‘false-positive’
FISH data, as such lesions may have been cured by
excision, so their spontaneous outcome is unknown.
Such ‘false-positive’ cases emphasize the need to
combine morphology and FISH data to achieve a
final diagnosis, and underline the lack of interest in
performing FISH for the diagnosis of typically
benign or malignant cases. Concerning false-nega-
tive cases, our three FISH-negative melanomas were
thin SSM (Breslow) between 1.2 and 2mm. How-
ever, the impact of thickness on FISH results was
Figure 3 Example of fluorescence in situ hybridization (FISH)-positive ambiguous lesion (case 56): (a) hematoxylin–eosin–saffron (HES)-
stained section showing spitzoid melanocytic tumor with large intraepidermal nests of spindle and epithelioid cells (100). Inset:
higher magnification ( 400). (b) FISH-positive result in the dermal component: *Nuclei showing Ras-responsive element-binding
protein-1 (RREB1) and cyclin D1 (CCDN1) gain myeloblastosis (MYB) deletion.
Table 3 Multivariate Cox proportional hazard regression model of significant prognostic parameters
Standard error w2 P-value Hazard ratio 95% CI
FISH 0.46380 0.2812 0.5959 1.279 (0.515, 3.174)
Age groupa 0.47056 2.0841 0.1488 0.507 (0.202, 1.275)
Expert diagnosisb 1.03969 7.4261 0.0064 17.000 (2.216, 130.45)
Locationc 0.46692 0.0210 0.8848 1.070 (0.428, 2.672)
a
Age group: o17 years (1), 17–59 years (0) and 459 years (1).
b
Expert diagnosis: malignant (A+) and benign (A).
c
Location: extremities (0) and axial (1).
Bold values are significant result.
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not shown by the study by Gerami et al.10 A recent
study proved the feasibility of this FISH test
for in situ (very thin) melanocytic lesions in the
so-called lentiginous junctional melanoma of the
elderly.14 In this study, three out of 19 in situ
melanomas were FISH negative. The main difficulty
concerning melanocytic lesions is to define the
gold standard for malignancy. It might be best to
use histopathological diagnosis. Yet, diagnoses
may differ between experts.4 It could also be to base
judgment on metastatic evolution. Yet, well-excised
melanomas may be cured and never metastasize.
A particularly doubtful diagnosis for thin lesions
has no impact on survival because complete
excision leads to complete remission. On the other
hand, the impact of a doubtful diagnosis in thick
melanocytic lesions is great because treatment and
follow-up are quite different. Therefore, our study
shows that the histopathological diagnosis com-
bined with FISH data could improve the accuracy of
diagnosis.
In our study, the most frequent FISH-positive
criterion was RREB1 gain (71%), as observed by
others.10,12,13 However in Morey’s study, CCDN1 gain
was as frequent as RREB1 gain in all type of
melanomas (70%),12 whereas we observed only
48% of CCDN1 gain in FISH-positive cases. CCDN1
gain has been found associated with ALM and
chronically sun-damaged skin melanoma sub-
types.13,15 In our series, ALM cases shared the same
chromosome aberration: CCDN1 gain and MYB
deletion. This is in agreement with the genetic
classification of melanomas based on sun exposure
proposed by Bastian et al.11 To improve the
diagnosis of acral melanoma or chronic sun-induced
damage melanomas, the analysis of KIT mutations
could provide ancillary data.16 Curtin et al16 found
KIT mutations in 36% of acral melanomas and 28%
of chronic sun-induced damage melanomas, but
never in melanoma on skin without chronic sun-
induced damage melanomas. The impact of FISH
analysis of melanoma has to be determined not only
for diagnostic purposes, but also for prognosis and
treatment.
In ambiguous melanocytic tumors, such genetic
analysis would primarily be very useful from a
diagnostic point of view, as it would help patholo-
gists to distinguish benign and malignant melano-
cytic lesions. Indeed, ambiguous lesions simulating
a melanoma represent the most frequent cause
of lawsuits for pathologists.9 Different genetic
approaches have been used to facilitate this differ-
ential diagnosis. Koh et al17 proposed a DNA
microarray-derived gene expression profiling
study after microdissection on formalin-fixed and
paraffin-embedded tissue sections of melanoma and
nevus, including difficult melanocytic lesions.
Thirty-six significant differentially expressed
genes were identified. In comparison with nevi,
melanomas expressed higher levels of genes pro-
moting signal transduction, transcription and cell
growth, but expression of L1CAM was reduced in
melanomas relative to nevi. For this reason, gene
signatures established using DNA microarray gene
expression profiling could be useful for distinguish-
ing melanomas from nevi as a supplement to
standard histology. The reproducibility of such an
approach has never been tested and its use in
routine practice may not be as robust as FISH
analysis.
Among ambiguous melanocytic tumors, the main
group of problematic lesions is Spitz tumors (45/90
in our study) as frequently reported in the literature
(eg, by Barnhill et al2). In our study, among 28 out of
the 45 Spitz tumors diagnosed as ‘favor malignant’
(Aþ ), 12 were FISH positive and six of them
underwent metastasis. Conversely, among the 16
FISH-negative ‘favor malignant’ Spitz cases, five
also displayed metastases showing that histopatho-
logical analysis remains the gold standard for
establishing the diagnosis of malignancy. A broader
spectrum of FISH probes and further genetic
analyses need to be evaluated in such FISH-negative
patients with metastatic outcome. Among the 14
‘favor benign’ (A) Spitz nevi, only one was FISH
positive (CCDN1 gain) and was even recurrence free
at 5-year follow-up. Two out of the three discordant
Spitz cases were FISH positive without unfavorable
course. Therefore, FISH positivity in ambiguous
cases may strengthen the diagnosis of malignancy
when at least one pathologist favors malignancy. In
such ‘favor malignant’ Spitz cases, a FISH-negative
result should not modify the expert interpretation.
In ‘favor benign’ ambiguous cases, negative FISH
data may lead to ‘conservative’ excision, as sug-
gested by others.18 Using the same FISH melanoma
kit, Gerami et al10 analyzed 27 ambiguous melano-
cytic tumors reviewed by two dermatopathologists
also mostly represented by Spitz tumors (24/27). Six
patients developed metastases and 21 remained free
with at least a follow-up period of 5 years. FISH was
positive in all six metastatic patients and in 6/21
non-metastatic patients. Among such Spitz tumors,
a technical difficulty for interpretation is polyploi-
dy. Eight of our nine polyploid cases corresponded
to Spitz tumors (seven ‘favor malignant’ and one
‘favor benign’). Interestingly, Isaac et al19 reported
four out of 41 Spitz nevi as polyploidy that were
confirmed by X-chromosome probe. The disease-
free survival times between FISH-positive and FISH-
negative patients were significantly different
(P¼ 0.003), as we observed in our study with a
trend for better prognosis for FISH-negative patients
(P¼ 0.07). This could be very useful in the future
because prognosis of melanocytic lesions seems to
be worse when the number of chromosomal anoma-
lies increases. Therefore, FISH data associated
with histopathological diagnosis could change the
patient’s management.
In our study, integration of FISH data along with
histopathological diagnosis was found relevant for
patient’s management as the FISH result was found
FISH for ambiguous melanocytic tumors
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to improve the specificity of histopathological
expert diagnosis alone (76% instead of 52%).
On the other hand, the sensitivity of the FISH test
alone was also improved (90 vs 43%). The most
difficult issue for ambiguous melanocytic lesions is
to determine what is the proof of malignancy
between expert diagnosis or metastatic outcome. If
expert diagnosis is taken to be the gold standard for
ambiguous melanocytic lesions, the specificity of
this FISH test is quite high (90.6%). However
between experts, the diagnostic reproducibility of
ambiguous melanocytic tumors is quite low.4 On the
other hand, if outcome is considered the most
important criterion, FISH was found to provide
good specificity (80%). Even metastatic outcome
is probably not so unfavorable in childhood
and teenage Spitz tumors, as recently shown by
Busam et al.20
Other applications of such a FISH melanoma kit
have been reported. It could be useful for microsta-
ging of melanoma, allowing the distinction between
melanoma arising on nevus vs nevoid melanoma.21
It could also be useful if it really changes the
treatment of patients, for example, with a thickness
greater than 1 or 1.5mm (according to the protocol),
leading to interferon treatment or other adjuvant
management such as sentinel node biopsy or
adjuvant vaccine therapy. Other FISH applications
have been reported to facilitate the differential
diagnosis between (I) epithelioid blue nevus and
cutaneous metastatic melanoma simulating blue
nevus22 or (ii) nevoid melanomas and mitotically
active nevi,23 (iii) conjunctival nevi from melano-
mas24 or (iv) intranodal nevus from metastatic
melanoma.25
In conclusion, a single genetic test allowing the
differential diagnosis between benign and malignant
ambiguous melanocytic lesions does not yet exist.
However, the practical value of the FISH test used in
this study was that it reinforced the histopathologi-
cal diagnosis of malignancy. In unequivocal mela-
nomas it was highly sensitive. In ambiguous
melanocytic tumors, especially in thick lesions,
slides should first be submitted to a referring
pathologist to improve the diagnosis and then a
positive FISH test would strengthen the diagnosis of
‘favor malignancy’. However, FISH testing did not
formally identify patients at risk of metastasis. In
unequivocal benign melanocytic ambiguous lesions,
caution should be taken if the FISH test is positive,
whereas a negative test would be an ancillary
argument for benignity in ‘favor benign’ cases.18 In
our opinion, FISH positivity alone without histo-
pathological diagnosis of malignancy should not
lead to modifying the patient’s treatment. Finally, in
cases with discordance between pathologists, the
value of a positive FISH test was high when a single
pathologist favored malignancy. Therefore, ambig-
uous lesions with doubtful or discordant histo-
pathological analyses should be tested by FISH. In
this group, FISH-positive cases should be managed
in the same way as malignant and ‘favor malignant’
cases. Further genetic testing should be conducted
on FISH-negative ‘favor malignant’ cases.
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